JFG
PTGX icon

Jefferies Financial Group’s Protagonist Therapeutics PTGX Stock Holding History

Jefferies Financial Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,000
Closed -$437K – 2115
2025
Q4 		$437K Sell
5,000
-816,503
-99% -$66.8M ﹤0.01% 1374
2025
Q3 		$54.6M Sell
821,503
-2,516
-0.3% -$143K 0.26% 57
2025
Q2 		$45.5M Buy
824,019
+192,126
+30% +$9.22M 0.38% 43
2025
Q1 		$30.6M Sell
631,893
-857,602
-58% -$35.9M 0.27% 54
2024
Q4 		$57.5M Sell
1,489,495
-325,201
-18% -$14.2M 0.34% 56
2024
Q3 		$81.7M Sell
1,814,696
-225,865
-11% -$9.13M 0.58% 24
2024
Q2 		$70.7M Buy
2,040,561
+860,000
+73% +$25.2M 0.75% 18
2024
Q1 		$34.2M Sell
1,180,561
-90,000
-7% -$2.45M 0.32% 43
2023
Q4 		$29.1M Buy
1,270,561
+435,000
+52% +$7.61M 0.19% 76
2023
Q3 		$13.9M Buy
835,561
+75,000
+10% +$1.46M 0.13% 123
2023
Q2 		$21M Buy
+760,561
New +$19M 0.19% 99
2023
Q1 		– Sell
-100,000
Closed -$1.09M – 1921
2022
Q4 		$1.09M Buy
+100,000
New +$844K 0.01% 843

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Jefferies Financial Group's PTGX Position: Q1 2026 in Review

Jefferies Financial Group sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 5,000 shares — an estimated $437K sold.

Jefferies Financial Group first reported a position in PTGX in Q4 2022 and held it in 12 quarters. The position peaked at $81.7M in Q3 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Jefferies Financial Group reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 5,000 Protagonist Therapeutics shares in Q1 2026, an estimated $437K.
  • Jefferies Financial Group first reported a position in Protagonist Therapeutics in Q4 2022 and held it in 12 quarters.
  • Jefferies Financial Group's Protagonist Therapeutics position peaked at $81.7M in Q3 2024.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.